Quick Answer
Emmaus Life Sciences, Inc. reported Total Revenue of $12.45 million for the year ending 2025.
- Emmaus Life Sciences, Inc. showed a decrease of -25.2% in Total Revenue from 2024 to 2025.
- This data is from Emmaus Life Sciences, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2018: $4.88 million | Q1 2019: $4.71 million | Q2 2019: $5.49 million | Q3 2019: $5.76 million | Q1 2020: $6.95 million | Q2 2020: $4.36 million | Q3 2020: $5.60 million | Q1 2021: $5.34 million | Q2 2021: $6.49 million | Q3 2021: $5.77 million | Q1 2022: $3.23 million | Q2 2022: $4.29 million | Q3 2022: $4.94 million | Q1 2023: $6.75 million | Q2 2023: $10.76 million | Q3 2023: $5.02 million | Q1 2024: $2.51 million | Q2 2024: $5.38 million | Q3 2024: $5.48 million | Q1 2025: $2.41 million | Q2 2025: $2.82 million | Q3 2025: $3.38 million.
- Over the full 8 years of available data (2018 to 2025), Emmaus Life Sciences, Inc.'s Total Revenue has declined by 24.3%.
- Historical annual values: Fiscal year 2025: $12.45 million | Fiscal year 2024: $16.65 million | Fiscal year 2023: $29.60 million | Fiscal year 2022: $18.39 million | Fiscal year 2021: $20.61 million | Fiscal year 2020: $23.17 million | Fiscal year 2019: $22.75 million | Fiscal year 2018: $16.46 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: